Budesonide and fluticasone propionate differentially affect the airway epithelial barrier

BACKGROUND: COPD patients have a higher risk of pneumonia when treated with fluticasone propionate (FP) than with placebo, and a lower risk with budesonide (BUD). We hypothesized that BUD and FP differentially affect the mucosal barrier in response to viral infection and/or cigarette smoke. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Heijink, I. H., Jonker, M. R., de Vries, M., van Oosterhout, A. J. M., Telenga, E., ten Hacken, N. H. T., Postma, D. S., van den Berge, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704248/
https://www.ncbi.nlm.nih.gov/pubmed/26739349
http://dx.doi.org/10.1186/s12931-015-0318-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704248/
https://www.ncbi.nlm.nih.gov/pubmed/26739349
http://dx.doi.org/10.1186/s12931-015-0318-z

Ejemplares similares